Pharmaceuticals Turn to “Niche‑Busters” for Sustained Growth
The pharmaceutical industry is in the middle of a meaningful shift in research strategy. For many years, research teams pursued blockbuster drugs—compounds designed to treat common conditions shared by large segments of the population. Novel treatments for high blood pressure, diabetes, elevated cholesterol, and other widespread ailments were the gold standard. A company able to successfully develop and market even one blockbuster could recoup years of research costs and enjoy significant returns until patent exclusivity expires and lower‑cost generics enter the market.
Historically, many companies avoided research into “orphan drugs,” meaning drugs aimed at diseases affecting relatively small patient populations. Orphan drug research was often viewed as cost‑prohibitive, and patients with rare diseases frequently faced limited therapeutic options. To address this gap, Congress passed the Orphan Drug Act in 1983, creating incentives intended to make rare‑disease drug development more economically viable.
That legislation helped catalyze a broader transformation in how companies think about R&D prioritization.
Today, the conversation is increasingly about “niche‑busting”—developing specialized, high‑value medicines targeting smaller, well‑defined populations. In many cases, this approach has gone hand-in-hand with scientific advances such as gene therapy, RNA‑targeted medicines, and precision oncology. Over time, companies have also begun applying lessons learned in rare‑disease development (diagnostics, trial design, biomarker strategy, and regulatory navigation) to more common conditions.
The Promise of Market Exclusivity
The Orphan Drug Act of 1983 codified several incentives for rare‑disease development, including tax credits for qualified clinical testing costs, research grants, and certain FDA fee waivers. But the centerpiece incentive has long been market exclusivity.
In the United States, an approved orphan drug indication generally receives seven years of orphan-drug exclusivity, which can prevent FDA approval of the “same drug” for the “same disease or condition” for that protected use during the exclusivity period. In the European Union, orphan medicines generally receive ten years of market exclusivity for the approved orphan indication (subject to certain conditions and potential reductions).
These incentives have been widely credited with accelerating rare‑disease research and development. FDA data and published analyses show that orphan designations and approvals have expanded dramatically since 1983.
Orphan drugs are no longer “niche” in the economic sense. Market analyses project that orphan products represent roughly one‑fifth of global prescription drug sales in the current decade, reflecting both growth in rare‑disease innovation and the commercialization success of certain high‑revenue orphan products.
Pricing Power (and the Tradeoffs)
Government incentives for rare‑disease research have reshaped the marketplace in at least two major ways.
On the positive side, these incentives have helped make it economically feasible for companies to pursue costly treatment modalities and invest in cutting‑edge research, such as gene therapy treatments designed to address the specific genetic mutations. Improved diagnostics (including next‑generation sequencing and biomarker identification) have also supported earlier and more accurate identification of rare diseases, enabling more targeted drug development.
On the other side of the ledger, orphan drugs can carry very high price tags—often tied to small patient populations, complex manufacturing, and long development timelines. One widely cited example is Soliris (eculizumab), developed by Alexion, which has been described in industry reporting as costing approximately $409,500 per year for certain patients (pricing varies across time and geographies). Alexion reported Soliris net product sales of $2.843 billion in 2016, illustrating how a successful orphan product can generate blockbuster‑level revenue despite serving relatively small populations.
Importantly, patients rarely pay list price out of pocket. Rebates, coverage design, patient assistance programs, and payer negotiation can materially change the net cost paid. Still, at a system level, high‑cost orphan drugs can create real budget pressure for payers and health systems—one reason orphan drug incentives, pricing, and exclusivity continue to be an active topic of policy discussion.
“Salami Slicing” and “Partial Orphans”
The allure of orphan‑drug incentives has also contributed to lifecycle and indication strategies that expand commercial value over time. Critics sometimes refer to certain approaches as “salami slicing” or developing “partial orphans,” meaning a sponsor seeks orphan status for a narrower indication and later pursues broader indications—sometimes within adjacent patient subsets or additional disease types.
A related dynamic is repurposing, where a product initially approved for a broader market later receives orphan designation for a rare condition. The practice itself is not inherently improper. Repurposing can create meaningful patient benefit. But observers have raised questions about whether some uses of orphan incentives align with the original policy intent. A Kaiser Health News (Kaiser Family Foundation) investigation, for example, reported that a meaningful share (roughly one-third) of orphan approvals involved products with multiple orphan approvals or products that were already approved for broader indications and later received orphan status for rare conditions.
One prominent example is Humira (adalimumab). Humira was approved by the FDA in 2002 to treat rheumatoid arthritis. FDA orphan‑designation records show Humira was then designated in 2005 for treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis) and later approved for that pediatric indication (with orphan exclusivity tied to the protected use). Humira later received additional orphan-related approvals for certain pediatric uses, each with indication‑specific exclusivity periods tied to those protected uses.
Vouchers: A Second Incentive Path
Another incentive mechanism is the Rare Pediatric Disease Priority Review Voucher (PRV) program. Under this program, a sponsor that obtains FDA approval for a qualifying rare pediatric disease drug may receive a transferable voucher that can be used to receive priority review of a future application, shortening FDA review time from the standard timeline to about six months.
Congress recently reauthorized the rare pediatric PRV program through September 30, 2029, as part of the Consolidated Appropriations Act of 2026. Because faster review can accelerate time to market, PRVs can carry substantial economic value and have been reported to sell for more than $100 million in private transactions.
The Path Forward
In many ways, medical research has come full circle. Pharmaceutical companies are no longer focused exclusively on mass‑market indications. The search for “niche‑busters”—treatments targeting smaller, discrete populations—is now a core strategy for many organizations. This shift has helped produce substantial scientific advances and, in some cases, those advances have translated into broader applications over time.
From an industry and risk perspective, the trend also has practical implications: narrower populations can mean more specialized trial designs, heavier reliance on biomarkers and real‑world evidence, complex supply chains, and heightened scrutiny around safety, pricing, promotion, and access. Whether the “niche‑buster” era ultimately produces more durable innovation and a sustainable policy balance will depend on how incentives, competition, and patient access evolve in the years ahead.
Authored by Lisa Krist, Berkley Life Sciences, VP, Chief Customer Focus Officer